Recursion Pharmaceuticals

RXRXNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$1.724 B

$3.22 +1.26%

Close of 7 Aug 2026

Revenue

$74.7M

#2617 by revenue

Earnings

-$644.8M

Loss-making

Shares outstanding

535,342,170

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#35MesoblastMESO$2.06B
#36Taysha Gene TherapiesTSHA$1.89B
#37Recursion PharmaceuticalsRXRX$1.72B
#38ImmunocoreIMCR$1.64B
#39Maze TherapeuticsMAZE$1.59B

Where these numbers come from

Share counts and financials for Recursion Pharmaceuticals are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.